Veeda Clinical Research Limited
Pharmaceuticals
₹415.00
0.00%
As of 09 Oct 2026
Indicative Price History
CIN
U73100GJ2004PLC044023
Market Cap (FY 25)
—
Revenue (FY 25)
₹609.73 Cr
EBITDA (FY 25)
₹136.43 Cr
PAT (FY 25)
₹-66.81 Cr
EBITDA Margin (FY 25)
22%
PAT Margin (FY 25)
-10.8%
ROE (FY 25)
-7.8%
Debt / Equity (FY 25)
0.47
Net Worth (FY 25)
₹855.76 Cr
About Company
Veeda Lifesciences – Investment SnapshotVeeda Lifesciences, established in 2004, is among India’s largest independent full-service Contract Research Organizations (CROs), offering comprehensive services from preclinical studies to late-stage clinical trials. With a recent rebranding and strategic global expansion, the company has strengthened its position in the evolving healthcare and pharmaceutical research landscape.Key Highlights:Global Reach: Acquired European CRO 'Heads,' enabling multi-geography trial Read more
Industry
Pharmaceuticals
Status
Private Company - Operating
Parent Company
Veeda Clinical Research Limited
Financial Highlights
Revenue (₹ Cr)
PAT (₹ Cr)
P&L (consolidated)
| ₹ Cr | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Revenue | 609.73 | 388.78 | 409.58 | 288.03 | 195.81 |
| Other Income | 11.41 | 19.21 | 10.63 | 5.08 | 38.57 |
| Total Expenses | 484.71 | 336.78 | 306.16 | 226.60 | 129.10 |
| EBITDA | 136.43 | 71.21 | 114.05 | 66.51 | 105.28 |
| Depreciation | 147.71 | 53.36 | 38.02 | 25.41 | 14.94 |
| EBIT | -11.28 | 17.85 | 76.03 | 41.10 | 90.34 |
| Finance Costs | 54.27 | 14.59 | 13.88 | 9.63 | 4.80 |
| PBT | -65.55 | 3.26 | 62.15 | 31.47 | 85.53 |
| Tax | 1.26 | 3.62 | 17.06 | 15.48 | 22.57 |
| PAT | -66.81 | -0.36 | 45.09 | -18.12 | 62.97 |
| EPS | N/A | N/A | N/A | N/A | 15.38 |
Shareholding Pattern
Hero Enterprise Ventures Pvt. Ltd.
4.59%
Dalmia Bharat Refractories Ltd.
2.29%
ValueQuest Capital LLP
2.29%
QRG Investments and Holdings Ltd.
1.71%
Singularity AMC LLP
0.23%
V L S Finance Ltd.
0.23%
Sabre Capital India Investment Advisors Pvt. Ltd.
0.13%
Nikhil Kishorchandra Vora
0.01%
Others / Public
88.52%
Financial Report FY2025
Financial Report · FY2025
Financial Report FY2024
Financial Report · FY2024
Financial Report FY2023
Financial Report · FY2023
Financial Report FY2022
Financial Report · FY2022
Financial Report FY2021
Financial Report · FY2021
Financial Report FY2020
Financial Report · FY2020
Financial Report FY2019
Financial Report · FY2019
Financial Report FY2018
Financial Report · FY2018
Financial Report FY2017
Financial Report · FY2017
Financial Report FY2016
Financial Report · FY2016
Financial Report FY2015
Financial Report · FY2015
Financial Report FY2014
Financial Report · FY2014
Financial Report FY2013
Financial Report · FY2013
Financial Report FY2012
Financial Report · FY2012
Financial Report FY2011
Financial Report · FY2011
reveliolabs.com
reveliolabs.com
Veeda Clinical Research Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
IndiaMedToday
IndiaMedToday
Agilent and Veeda Lifesciences Launch Joint Analytical Center of Excellence to Accelerate GLP‑1 and Complex Biologics Development Services
Agilent and Veeda Lifesciences launch a joint Center of Excellence in Bengaluru to accelerate GLP‑1 and complex biologics development.
Express Pharma
Express Pharma
Agilent and Veeda Lifesciences launch Joint Analytical Center of Excellence to accelerate GLP‑1, complex biologics development services
Agilent Technologies, a global leader in analytical and laboratory solutions, today announced a strategic collaboration with Veeda...
Tracxn
Tracxn
Veeda Lifesciences - 2026 Latest Shareholding & Valuation
Explore Veeda Lifesciences' latest cap table with a round-by-round shareholding summary, key stakeholders, ownership breakdown,...
IndiaMedToday
IndiaMedToday
Cytiva, Veeda Lifesciences drive biopharma innovation with new host cell protein services centre - IndiaMedToday
Pharmabiz.com
Pharmabiz.com
Cytiva and Veeda Lifesciences drive biopharma innovation with new host cell protein services center
Cytiva and Veeda Lifesciences drive biopharma innovation with new host cell protein services center. Our Bureau, Bengaluru
IPO Watch
IPO Watch
Veeda Clinical IPO Date, Review, Price, Allotment Details - IPO Watch
The Times of India
The Times of India
IPO rush in India’s pharma sector: Sector eyes Rs 12,000 crore fundraising; 15 companies ready to enter m - The Times of India
BioXconomy
BioXconomy
Veeda buys Heads just weeks after appointing new CEO
Indian clinical research organization (CRO) Veeda Clinical Research Limited has acquired European headquartered counterpart Heads, citing its global...
Medical Dialogues
Medical Dialogues
Veeda Clinical Research Gets Expert Committee Nod To Conduct BA/BE Study Of Ibrutinib For Export
New Delhi: Veeda Clinical Research Limited got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...